Tumor/ disorder type | Interacting molecules and pathways | Cell lines | Function | References |
---|---|---|---|---|
Gastric cancer | miR-106a-3p, APC, Wnt/β-catenin pathway | SUN-216, BGC-823, AGS, BGC-803, NUGC4, MKN74, MKN45, SGC-7901, HGC-27 and GES-1 | ∆ LINC01133: ↑ proliferation, ↑ migration, ↑ EMT process | [21] |
miR-576-5p, SST | GC cells | ↑ LINC01133: ↓ malignant phenotypes | [22] | |
Epithelial ovarian cancer | miR-495-3p, TPD52 | SKOV3, A2780, IOSE8 | ↑ LINC01133: ↑ migration, ↑ invasion | [14] |
Ovarian cancer | miR-205, LRRK2 | IOSE80, SKOV-3, HO-8910, and OVCAR-8 | ↑ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion | [15] |
Hepatocellular carcinoma | PI3K/AKT signaling pathway | HepG2, Hep3B, MHCC-97 L, SK-Hep-1, and MHCC-97 H, HL-7702 | ∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion, ↓ colony formation, ↑ apoptosis, ↑ G1 phase arrest | [23] |
miR-199a-5p, SNAI1, EMT, ANXA2/STAT3/cyclin D1 signaling | MHCC97L, MHCC97H, and HCCLM3, Hep3B, HepG2, PLC/PRF/5, and Huh7 | ∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion, ↓ colony formation ↑ LINC01133: ↑ proliferation, ↑ migration, ↑ invasion, ↑ colony formation, ↑ EMT process | [19] | |
Cervical cancer | miR-4784, AHDC1 | NC104, Hela, ME-180, C33A and MS751 | ∆ LINC01133: ↓ proliferation, migration, ↓ invasion, ↓ EMT process | [24] |
miR-30a-5p, FOXD1 | HeLa, HT-3, C33A, SiHa | ↑ LINC01133: ↑ proliferation, ↑ migration, ↑ invasion, ↓ apoptosis | [16] | |
Breast cancer | EZH2, SOX4 | MDA-MB‐231, SKBR‐3, MDA‐MB‐468, ZR‐75‐1, BT474, MCF‐7 and T47D, MCF‐10 A | ∆ LINC01133: ↑ viability, ↑ migration, ↑ invasion ↑ LINC01133: ↓ viability, ↓ migration, ↓ invasion | [25] |
miR-199a, FOXP2, KLF4 (Pluripotency Master Regulator) | DA-MB-231, MDA-MB-468, HCC1937, T47D, MCF7, ZR-75-1, BT-20, HCC1143, BT549, and Hs578T, HCC70, 4T1, and MCF10A | ↑ LINC01133: ↑ SC-Like Traits in TNBC Cells | [17] | |
Nasopharyngeal carcinoma | YBX1 | NP69, CNE-1, CNE-2, 5-8 F, 6-10B, and SUNE-1 | ∆ LINC01133: ↑ proliferation, ↑ migration, ↑ invasion, ↑ colony formation, ↑ EMT process ↑ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion, ↓ colony formation, ↓ EMT process | [26] |
Renal cell carcinoma | miR-30b-5p, Rab3D | HKC, ACHIN, A498, SN12PM6, and 786-O | ∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion | [27] |
Endometrial carcinoma | Ishikawa and HEC-1-A cells | ∆ LINC01133: ↓ proliferation, migration, ↓ invasion | [28] | |
Pancreatic cancer | C/EBPβ, CCNG1 | BXPC3, CFPAC1, PANC1, and SW1990, CAPAN-2 | ∆ LINC01133: ↓ proliferation | [29] |
DKK1, Wnt signaling pathway | SW1990, Capan1, AsPc1, PANC − 1, BxPC − 3, and HPDE | ↑ LINC01133: ↑ growth, ↑ proliferation, ↑ migration, ↑ metastasis, and ↑ invasion | [18] | |
miR-216a -5p, TPT1, mTORC1 pathway | SW1990, PANC1, Capan-2, BxPC-3, and HPDE6 | ↑ miR-216a -5p (a target of LINC01133): ↓ proliferation, ↓ colony formation, ↑ cell cycle arrest ∆ LINC01133: ↓ proliferation, migration, ↓ invasion | [30] | |
Periostin, EZH2, AXIN2, Wnt/β-catenin pathway | CFPAC-1, AsPC-1, Panc-1, SW1990, HPDE, human PSCs | ∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion, ↑ apoptosis ↑ LINC01133: ↑ proliferation, ↑ migration, ↑ invasion, ↓ apoptosis Periostin up-regulated LINC01133. | [31] | |
Oral squamous cell carcinoma | GDF15 | NOK, CAL27, HN4, and 293FT | ∆ LINC01133: did not affect proliferation, ↑ migration, ↑ invasion | [32] |
Osteosarcoma | miR-422a | MG63, Saos-2, HOS, U2-OS, NHOst, and HEK-293 | ∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion | [33] |
Colorectal cancer | TGF-β signaling pathway, SRSF6 | HT29, HCT8, LS513, SW620, and HCT11 | ∆ LINC01133: ↑ EMT process, ↑ metastasis TGF-β signaling pathway inhibited LINC01133. | [34] |
Lung cancer | KLF2, P21 and E-cadherin, EZH2 and LSD1 | PC9, SPC-A1, NCI-H1975, H1299, and A549, H520, H1703, and SK-MES-1 | ∆ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion, ↑ apoptosis | [20] |
H1703 | ∆ LINC01133: ↓ migration, ↓ invasion | [35] | ||
Bladder cancer | Wnt signaling pathway | V-HUC‐1, T24 and J82 | ↑ LINC01133: ↓ proliferation, ↓ migration, ↓ invasion | [36] |